Ehlers Danlos syndrome & dysautonomia links 10/16/11

I’ve always thought that the timing of the slow, lingering FDA fiasco with Midodrine was odd, since it coincided with Chelsea Theraputics’ trying to get that Northera orthostatic hypotension drug to market. Chelsea Theraputics’ previous clinical studies on Northera didn’t do well this year UPDATE 2-Chelsea Therapeutics shares fall on Northera study data (Reuters) so they redesigned the studies.

This week shares were up:

Chelsea Therapeutics asks FDA to approve Northera

Their application is being fast-tracked for FDA approval within 60 days, LOL.

From what I understand, Northera crosses the blood-brain barrier, while Midodrine does not.

Both comments and trackbacks are currently closed.
%d bloggers like this: